Niv Yaron, Hazazi Rachel, Waked Amal, Lederfein Tami, Achiel Karin
Department of Gastroenterology, Rabin Medical Center, Beilinson Hospital, Tel Aviv University, Petach Tikva, Israel.
Dig Dis Sci. 2008 May;53(5):1211-4. doi: 10.1007/s10620-007-0016-x. Epub 2007 Oct 16.
In developing countries the recurrence rate of Helicobacter pylori after successful eradication therapy is as high as 42%, while in developed countries it is estimated to be less than 3%. Such figures are very important in terms of determining clinical strategy and outcome.
To estimate the recurrence rate of H. pylori in Israel using the database of the "Central H. Pylori Laboratory of Clalit Health Services".
The database was searched for patients who had undergone the [(13)C]-urea breath test ([(13)C]-UBT) for validation of the successful eradication of H. pylori or for evaluation of dyspepsia 7 years previously and for whom the result had been negative. These patients were invited to participate in the trial, fill a symptom questionnaire and undergo another [(13)C]-UBT.
A In total, 65 patients participated; of these, 26 patients had tested negative in the first( 13)CUBT, indicating the successful eradication of H. pylori (Group A), and 39 had been tested for dyspepsia (Group B). One patient in each group had a positive [(13)C]-UBT - 3.84% in Group A and 2.56% in Group B (non-significant difference, NS). The mean annual H. pylori recurrence rate was calculated to be 0.55% and 0.37% in Group A and Group B patients, respectively (NS).
Our results shown a very low re-infection or new infection rates in Israeli adults and are in line with other trials in developed countries; they do not support the a retesting program for patients after a successful eradication therapy.
在发展中国家,幽门螺杆菌根除治疗成功后的复发率高达42%,而在发达国家,这一比例估计低于3%。这些数据对于确定临床策略和治疗结果非常重要。
利用“克拉利特健康服务中心幽门螺杆菌中央实验室”的数据库评估以色列幽门螺杆菌的复发率。
在数据库中搜索7年前接受过[(13)C] - 尿素呼气试验([(13)C] - UBT)以验证幽门螺杆菌根除是否成功或评估消化不良且结果为阴性的患者。邀请这些患者参与试验,填写症状问卷并再次接受[(13)C] - UBT。
共有65名患者参与;其中,26名患者首次[(13)C] - UBT检测呈阴性,表明幽门螺杆菌根除成功(A组),39名患者接受了消化不良检测(B组)。每组各有1名患者[(13)C] - UBT呈阳性——A组为3.84%,B组为2.56%(无显著差异,NS)。A组和B组患者的幽门螺杆菌年平均复发率分别计算为0.55%和0.37%(无显著差异)。
我们的结果显示,以色列成年人的再感染或新感染率非常低,与发达国家的其他试验结果一致;不支持对幽门螺杆菌根除治疗成功后的患者进行重新检测的计划。